Pembrolizumab (new indication: small intestine cancer with MSI-H or dMMR tumors, pretreated patients)

Subject:

• Active Sustance: Pembrolizumab
• Name: Keytruda®
• Therapeutic area: Small intestine cancer 
• Pharmaceutical company: MSD Sharp & Dohme GmbH

Time table:

• Start: 01.08.2022
• Final decision by G-BA: 19.01.2023

Final decision:

• No additional benefit proved